FDA Grants Orphan Drug Designation To Novartis’ Rapcabtagene Autoleucel For Treatment Of Idiopathic Inflammatory Myopathies

The FDA has granted orphan drug designation to Novartis' Rapcabtagene Autoleucel for the treatment of idiopathic inflammatory myopathies. This designation is intended to encourage the development of treatments for rare diseases. The approval may impact Novartis' market position in the specialty pharmaceuticals sector, although specific financial implications were not detailed in the article.